摘要
目的了解我院非瓣膜性房颤住院患者华法林临床应用情况,总结临床用药经验,为临床用药提供参考,探讨开展华法林临床药学监护的意义。方法查阅2012年1月至2014年12月我院第一心血管内科非瓣膜性房颤患者726例,并对抗凝方案的种类、华法林用药剂量、国际标准化比值（INR）监测等进行系统的回顾性调查分析。结果我院房颤患者常用抗凝方案包括双联抗血小板治疗、阿司匹林抗栓治疗和华法林等抗凝治疗。初始国际标准化比值（INR）为2.0~3.0的病例占13.8%,调整剂量后有43.4%的患者国际标准化比值（INR）达标。结论目前华法林的临床应用仍存在不足,继续提高人们对华法林的认知度和房颤的抗凝意识、积极开展华法林临床药学监护具有重要意义。
OBJECTIVE To understand the application of warfarin hospitalized patients with non-valvular atrial fibrillation,summarize the clinical experience and provide reference for clinical medication,and explore the significance of clinical pharmaceutical care for warfarin. METHODS The information of 726 cases with non-valvular atrial fibrillation hospitalized in the first cardiovascular ward from January 2012 to December 2013 were retrospectively collected and analyzed in the aspect of types of anticoagulant solution,warfarin dosage and INR monitoring. RESULTS The anticoagulation solution commonly used in our patients with atrial fibrillation included dual antiplatelet therapy,aspirin antithrombotic therapy and warfarin anticoagulant therapy. 13. 8% of the cases had initial INR of 2. 0- 3. 0,and 43. 4% of the cases attained INR target after dosage adjustment. CONCLUSION At present the clinical application of warfarin still exists deficiencies. It is necessary to continue to raise people＇s awareness of warfarin and atrial fibrillation anticoagulant.Active clinical pharmaceutical care for warfarin is of great significance.
出处
《中国药学杂志》
CAS
CSCD
北大核心
2015年第22期2000-2003,共4页
Chinese Pharmaceutical Journal
关键词
华法林
心房颤动
临床药师
调查分析
药学监护
慢病管理
warfarin
atrial fibrillation
clinical pharmacist
investigation analysis
pharmaceutical care
chronic disease management
